Neurology
Safety and Outcomes of Dabigatran Reversal With Idarucizumab Before IV Thrombolysis in Acute Ischemic Stroke
Real-world registry data suggest that reversing dabigatran with idarucizumab before IV thrombolysis in acute ischemic stroke is safe and yields outcomes similar to patients not on oral anticoagulants.
